Aliases & Classifications for Papilloma

MalaCards integrated aliases for Papilloma:

Name: Papilloma 12 56 15 74
Papillomatosis 12 56 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2615
MeSH 45 D010212
NCIt 51 C3713 C7440
SNOMED-CT 69 23730008 82049002

Summaries for Papilloma

Disease Ontology : 12 A cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary : Papilloma, also known as papillomatosis, is related to inverted papilloma and bladder transitional cell papilloma. An important gene associated with Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and PI3K-Akt signaling pathway. The drugs Cidofovir and Chlorhexidine have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and skin, and related phenotypes are growth/size/body region and digestive/alimentary

Wikipedia : 77 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Related Diseases for Papilloma

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 558)
# Related Disease Score Top Affiliating Genes
1 inverted papilloma 34.3 CDKN2A KRT13 KRT20 TP53
2 bladder transitional cell papilloma 34.0 CDKN1A TP53
3 frontal sinus inverted papilloma 33.9 KRT13 KRT5
4 inverted transitional papilloma 33.7 CDKN2A KRT5
5 anogenital venereal wart 32.7 CDKN2A TP53 UBE3A
6 urinary tract papillary transitional cell benign neoplasm 32.5 FGFR3 KRT20 TP53
7 li-fraumeni syndrome 32.1 CDKN1A CDKN2A PTEN TP53
8 palmoplantar keratoderma, epidermolytic 31.8 FLG KRT10 KRT14
9 keratosis, seborrheic 31.3 FGFR3 KRT10 KRT5
10 suppressor of tumorigenicity 3 31.1 CDKN1A CDKN2A RB1 TP53 UBE3A
11 oral cancer 30.9 CDKN2A KRT13 TP53
12 oropharynx cancer 30.8 CDKN2A KRT14 KRT5 TP53
13 squamous cell carcinoma 30.7 CDKN2A FGFR3 IVL PTEN RB1 TP53
14 in situ carcinoma 30.7 CDKN2A KRT14 KRT5 TP53
15 verrucous carcinoma 30.7 CDKN2A KRT10 RB1 TP53
16 retinoblastoma 30.6 CDKN1A CDKN2A RB1 TP53
17 cervical squamous cell carcinoma 30.5 CDKN2A KRT8 TP53
18 adenocarcinoma 30.5 CDKN2A FGFR3 PTEN RB1 TP53
19 cholangiocarcinoma 30.5 CDKN2A KRT20 KRT8 PTEN TP53
20 lymphoepithelioma-like carcinoma 30.5 KRT20 KRT5 KRT8
21 ductal carcinoma in situ 30.4 KRT14 KRT5 KRT8 TP53
22 keratoacanthoma 30.3 CDKN1A FLG KRT10 TP53
23 cervical cancer 30.3 CDKN1A CDKN2A FGFR3 KRT14 KRT5 PTEN
24 transitional cell carcinoma 30.3 CDKN2A FGFR3 KRT20 KRT8 PTEN TP53
25 bowenoid papulosis 30.2 CDKN2A FLG
26 bladder cancer 30.2 CDKN1A CDKN2A FGFR3 KRT20 RB1 TP53
27 bladder squamous cell carcinoma 30.2 CDKN2A TP53
28 tongue cancer 30.1 CDKN1A CDKN2A KRT13 TP53
29 esophageal cancer 30.1 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
30 vulvar intraepithelial neoplasia 30.1 KRT10 TP53
31 endocervical adenocarcinoma 30.1 CDKN2A KRT20 TP53
32 non-invasive bladder papillary urothelial neoplasm 30.1 FGFR3 TP53
33 bladder urothelial carcinoma 30.1 FGFR3 KRT20 RB1 TP53
34 squamous cell carcinoma, head and neck 30.1 CDKN1A CDKN2A FGFR3 PTEN RB1 TP53
35 nasal cavity squamous cell carcinoma 30.1 CDKN2A KRT5 KRT8
36 cervical adenocarcinoma 30.0 CDKN1A CDKN2A KRT20 TP53
37 adenosquamous carcinoma 30.0 KRT5 KRT8 TP53
38 basaloid squamous cell carcinoma 30.0 CDKN2A KRT13 KRT14 KRT8 TP53
39 actinic keratosis 30.0 CDKN2A FLG KRT20 TP53
40 cervix carcinoma 29.9 CDKN2A FGFR3 TP53
41 lichen planus 29.9 FLG IVL KRT10 KRT13 TP53
42 small cell cancer of the lung 29.8 CDKN2A KRT20 PTEN RB1 TP53
43 lung cancer susceptibility 3 29.7 CDKN1A CDKN2A FGFR3 KRT20 TP53
44 giant cell glioblastoma 29.7 FGFR3 PTEN TP53
45 glioblastoma 29.7 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
46 basal cell carcinoma 29.6 IVL KRT10 KRT20 KRT8 TP53
47 gastric adenocarcinoma 29.6 CDKN2A CDKN2B KRT20 KRT8 PTEN TGFA
48 adenoid cystic carcinoma 29.6 KRT14 KRT20 KRT5 PTEN TP53
49 large cell acanthoma 29.6 KRT10 KRT14 KRT5
50 keratosis 29.5 FGFR3 FLG IVL KRT10

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma

Symptoms & Phenotypes for Papilloma

MGI Mouse Phenotypes related to Papilloma:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.29 AMOT CDKN1A CDKN2A FGFR3 KRT14 KRT5
2 digestive/alimentary MP:0005381 10.22 CDKN1A CDKN2A FGFR3 KRT14 KRT5 KRT8
3 mortality/aging MP:0010768 10.22 AMOT CDKN1A CDKN2A CDKN2B FGFR3 KRT14
4 integument MP:0010771 10.17 CDKN1A CDKN2A CDKN2B FGFR3 KRT14 KRT5
5 endocrine/exocrine gland MP:0005379 10.15 CDKN1A CDKN2A CDKN2B KRT14 PTEN RB1
6 embryo MP:0005380 10.11 AMOT CDKN1A CDKN2A KRT8 PTEN RB1
7 craniofacial MP:0005382 10.08 CDKN1A FGFR3 KRT14 KRT5 RB1 TGFA
8 adipose tissue MP:0005375 10.02 CDKN1A KRT14 PTEN RB1 TGFA TP53
9 neoplasm MP:0002006 9.97 CDKN1A CDKN2A CDKN2B FGFR3 KRT14 PTEN
10 hearing/vestibular/ear MP:0005377 9.93 CDKN1A FGFR3 KRT14 KRT8 RB1 TP53
11 no phenotypic analysis MP:0003012 9.92 CDKN1A CDKN2A CDKN2B FGFR3 KRT5 RB1
12 reproductive system MP:0005389 9.9 CDKN1A CDKN2A CDKN2B FGFR3 KRT14 KRT8
13 pigmentation MP:0001186 9.65 CDKN2A KRT14 PTEN RB1 TP53
14 respiratory system MP:0005388 9.5 CDKN1A CDKN2A FGFR3 KRT14 PTEN RB1
15 vision/eye MP:0005391 9.23 CDKN1A CDKN2A FGFR3 KRT14 PTEN RB1

Drugs & Therapeutics for Papilloma

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 278)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cidofovir Approved Phase 4,Phase 2,Phase 1 113852-37-2 60613
2
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
3
Polihexanide Approved, Investigational Phase 4 28757-47-3
4
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99011-02-6 57469
5
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
6 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Disinfectants Phase 4
15 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Biguanides Phase 4
17 Chlorhexidine gluconate Phase 4
18 Anti-Infective Agents, Local Phase 4
19 Hypoglycemic Agents Phase 4
20 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
21 MF59 oil emulsion Phase 4
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
23 Interferon Inducers Phase 4,Phase 2,Phase 3,Phase 1
24 interferons Phase 4,Phase 2,Phase 3,Phase 1
25 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Insulin, Globin Zinc Phase 4,Phase 3
27 insulin Phase 4,Phase 3
28
Azithromycin Approved Phase 3,Not Applicable 83905-01-5 55185 447043
29
Cetuximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 205923-56-4 56842117 2333
30
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
31
tannic acid Approved Phase 3 1401-55-4
32
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
34
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
35
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
36
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
37
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
38
Promethazine Approved, Investigational Phase 3 60-87-7 4927
39
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
40
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6 774
41
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
42
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
43
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
44
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
45
Zinc sulfate Approved, Investigational Phase 3,Not Applicable 7733-02-0
46
Zinc Approved, Investigational Phase 3,Not Applicable 7440-66-6 32051
47 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
48
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2 388082-78-8, 231277-92-2 208908 9941095
49 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Hormones Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 429)
# Name Status NCT ID Phase Drugs
1 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Use of Cidofovir for Recurrent Respiratory Papillomatosis Completed NCT00205374 Phase 4 Cidofovir;Placebo
4 A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men Completed NCT01431079 Phase 4
5 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
6 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
7 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
8 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
9 MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Completed NCT02225327 Phase 4
10 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
11 Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study) Recruiting NCT03391921 Phase 4
12 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
13 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
14 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
15 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
16 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
17 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
18 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
19 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
20 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
21 Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine Completed NCT00316706 Phase 3
22 Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. Completed NCT00196924 Phase 3
23 Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 Completed NCT00169494 Phase 3
24 Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) Completed NCT00380367 Phase 3
25 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
26 Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 Completed NCT00196937 Phase 3
27 Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) Completed NCT01862874 Phase 3
28 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3
29 A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) Completed NCT02114385 Phase 3
30 Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
31 Safety and Tolerability Study of V501 in Japanese Boys (V501-200) Completed NCT02576054 Phase 3
32 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
33 Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years Completed NCT00345878 Phase 3
34 Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women Completed NCT00344032 Phase 3
35 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
36 Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) Completed NCT00157950 Phase 3
37 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects Completed NCT00578227 Phase 3
38 A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years Completed NCT00485732 Phase 3
39 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
40 Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls Completed NCT01381575 Phase 3
41 Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age Completed NCT00552279 Phase 3
42 ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
43 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
44 A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). Completed NCT01254643 Phase 3
45 Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea Completed NCT01955252 Phase 3 Azithromycin
46 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
47 Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age Completed NCT00492544 Phase 3
48 Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Completed NCT00456807 Phase 3
49 A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls Completed NCT02562508 Phase 3
50 A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Papilloma

Anatomical Context for Papilloma

MalaCards organs/tissues related to Papilloma:

42
Breast, Testes, Skin, Cervix, Lung, Kidney, Bone

Publications for Papilloma

Articles related to Papilloma:

(show top 50) (show all 4085)
# Title Authors Year
1
Electrocoagulation of biliary papillomatosis during choledochoscopy. ( 30658359 )
2019
2
Surgical treatment of malignant biliary papillomatosis invading adjacent organs: A case report. ( 30705903 )
2019
3
Is human papillomavirus associated with breast cancer or papilloma presenting with pathologic nipple discharge? ( 30785026 )
2019
4
Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins. ( 30642295 )
2019
5
Hemoptysis and Bronchiolitis Obliterans in Children with Recurrent Respiratory Papillomatosis: Adverse Reactions to Nebulized Cidofovir. ( 30611599 )
2019
6
Prospective cohort study examining cervical cancer screening methods in HIV-positive and HIV-negative Cambodian Women: a comparison of human papilloma virus testing, visualization with acetic acid and digital colposcopy. ( 30804036 )
2019
7
Health professionals' willingness to pay and associated factors for human papilloma virus vaccination to prevent cervical cancer at College of Medicine and Health Sciences University of Gondar, Northwest Ethiopia. ( 30678735 )
2019
8
New prophylactics human papilloma virus (HPV) vaccines against cervical cancer. ( 30370796 )
2019
9
Association of Base Excision Repair Gene hOGG1 Ser326Cys Polymorphism with Susceptibility to Cervical Squamous Cell Carcinoma and High-Risk Human Papilloma Virus Infection in a Chinese Population. ( 30648893 )
2019
10
Apparent diffusion coefficients are closely related with high-risk human papilloma virus infection in cervical squamous cell carcinoma patients. ( 30722670 )
2019
11
The management of numerous carcinomatous sequelae of human papilloma virus in an allogeneic stem cell transplant patient with chronic graft versus host disease. ( 30733986 )
2019
12
Intraductal papilloma of the male breast: a case report and review of the literature. ( 30788101 )
2019
13
Intraductal papilloma of the breast - management. ( 30860277 )
2019
14
Origin site-based staging system of sinonasal inverted papilloma for application to endoscopic sinus surgery. ( 30554455 )
2019
15
Outcomes of sinonasal inverted papilloma resection by surgical approach: an updated systematic review and meta-analysis. ( 30748098 )
2019
16
Cervical nodal metastasis after malignant conversion of sinonasal inverted papilloma: Report of a rare case and literature review. ( 30846175 )
2019
17
Surgical outcomes of sinonasal inverted papilloma: a 17 year review. ( 30852156 )
2019
18
EGFR and KRAS mutations in Chinese patients with sinonasal inverted papilloma and oncocytic papilloma. ( 30916792 )
2019
19
Comprehensive analysis of HPV infection, EGFR exon 20 mutations and LINE1 hypomethylation as risk factors for malignant transformation of sinonasal-inverted papilloma to squamous cell carcinoma. ( 30411788 )
2019
20
Histopathological features of juvenile-onset laryngeal papillomatosis related to severity. ( 30623508 )
2019
21
Management of laryngeal papillomatosis using coblation: another option of surgical intervention. ( 30798335 )
2019
22
Implication of low risk human papillomaviruses, HPV6 and HPV11 in laryngeal papillomatosis in Burkina Faso. ( 30799210 )
2019
23
Pathological mechanisms of laryngeal papillomatosis based on laryngeal epithelial characteristics. ( 30828624 )
2019
24
Gallbladder Papilloma in a Child Unmasking Metachromatic Leukodystrophy: A Case Report With Review of Literature. ( 30912695 )
2019
25
Prevalence of high-risk human papilloma virus in liquid-based cervical samples from Turkish women with normal and abnormal cytology. ( 30457213 )
2019
26
A 17-year-old woman with a solitary, mixed squamous cell and glandular papilloma of the bronchus. ( 30519472 )
2019
27
Posterior fossa choroid plexus papilloma with focal ependymal differentiation in an adult patient: A case report and literature review. ( 30546813 )
2019
28
An ultrasensitive label free human papilloma virus DNA biosensor using gold nanotubes based on nanoporous polycarbonate in electrical alignment. ( 30598155 )
2019
29
Isolated Schneiderian papilloma of the middle ear cleft. ( 30610035 )
2019
30
Vanishing diffuse leptomeningeal contrast enhancement in an infant with choroid plexus papilloma. ( 30617713 )
2019
31
Human papilloma virus identification in ocular surface squamous neoplasia by p16 immunohistochemistry and DNA chip test: A strobe-compliant article. ( 30633172 )
2019
32
Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology. ( 30650527 )
2019
33
Mixed squamous cell and glandular papilloma of the lung: A case report of a novel mutation in the BRAF gene and coexistent HPV infection, possible relationship to ciliated muconodular papillary tumor. ( 30664316 )
2019
34
Validation of the HPV Impact Profile (HIP) in Portuguese Women with Human Papilloma Virus. ( 30686056 )
2019
35
Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events. ( 30693675 )
2019
36
Expression of p16 and p27 protein in cervical exfoliated cells and its relationship with high risk human papilloma virus in cervical lesions. ( 30693740 )
2019
37
Prophylactic human papilloma virus vaccination in head and neck: indications and future perspectives. ( 30694913 )
2019
38
Excision recommended in high-risk patients: Revisiting the diagnosis of papilloma on core biopsy in the context of patient risk. ( 30697873 )
2019
39
Prevalence of high-risk human papilloma virus in women with high-grade squamous cell intraepithelial lesions in Botswana using Abbott RealTime HPV assay. ( 30699172 )
2019
40
Stereophotogrammetric 3D photography is an accurate and precise planimetric method for the clinical visualization and quantification of HPV-induced skin lesions. ( 30720900 )
2019
41
Molecular Genetic Study to Detect Prevalence of High-risk Human Papilloma Virus Strains (type 16 and 18) in Cervical Lesions and Asymptomatic Healthy Subjects of Rural Central India. ( 30745737 )
2019
42
Molecular Diagnosis of Human Papilloma Virus by PCR. ( 30755567 )
2019
43
High-risk human papilloma virus testing improves diagnostic performance to predict moderate-to-high grade anal intraepithelial neoplasia in HIV-infected men who have sex with men in low-to-absent cytological abnormalities. ( 30770528 )
2019
44
Impact of human papilloma virus in patients with oral and oropharyngeal squamous cell carcinomas. ( 30777194 )
2019
45
Two-Year Results of Community-Based Screening Program for Human Papilloma Virus DNA in Çorum Province. ( 30793760 )
2019
46
Prevalence of epithelial abnormalities and high-risk human papilloma virus in cervicovaginal Pap smears of population subgroups as a guide toward evidence-based best practice. ( 30801970 )
2019
47
Human Papilloma Virus Infection. ( 30817264 )
2019
48
Knowledge, Attitudes and Practices Regarding Human Papilloma Virus Communication and Vaccine Advocacy Among Minnesota Dentists and Dental Hygienists. ( 30819844 )
2019
49
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. ( 30838648 )
2019
50
Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis. ( 30842242 )
2019

Variations for Papilloma

Expression for Papilloma

Search GEO for disease gene expression data for Papilloma.

Pathways for Papilloma

Pathways related to Papilloma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 FGFR3 FLG IVL KRT10 KRT13 KRT14
2
Show member pathways
12.95 CDKN1A FGFR3 PTEN RB1 TGFA TP53
3
Show member pathways
12.88 CDKN1A CDKN2A PTEN RB1 TGFA TP53
4
Show member pathways
12.71 CDKN1A CDKN2A CDKN2B PTEN RB1 TGFA
5 12.69 CDKN1A CDKN2A CDKN2B FGFR3 PTEN RB1
6
Show member pathways
12.57 CDKN1A CDKN2A CDKN2B RB1 TP53
7 12.52 CDKN1A CDKN2A FGFR3 PTEN TP53
8 12.5 AMOT KRT10 KRT13 KRT20 KRT5 KRT8
9 12.46 CDKN1A CDKN2A RB1 TP53
10
Show member pathways
12.38 CDKN1A CDKN2A PTEN RB1 TP53
11 12.37 CDKN1A CDKN2A CDKN2B RB1 TP53
12 12.36 CDKN1A CDKN2A CDKN2B RB1 TP53
13
Show member pathways
12.35 CDKN1A CDKN2A CDKN2B FGFR3 PTEN RB1
14
Show member pathways
12.33 CDKN1A CDKN2A CDKN2B RB1 TP53
15
Show member pathways
12.24 CDKN1A PTEN RB1 TP53
16
Show member pathways
12.22 CDKN1A FGFR3 PTEN RB1 TP53
17
Show member pathways
12.21 CDKN1A CDKN2A CDKN2B RB1
18 12.18 CDKN1A CDKN2A CDKN2B RB1 TP53 UBE3A
19 12.13 CDKN1A FGFR3 PTEN TP53
20 12.04 CDKN1A CDKN2A RB1 TP53 UBE3A
21 12.03 CDKN1A PTEN RB1 TGFA TP53
22 12 CDKN1A CDKN2A PTEN TP53
23
Show member pathways
11.97 KRT13 KRT14 KRT5 KRT8
24 11.94 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
25 11.92 CDKN1A CDKN2A PTEN RB1 TP53
26 11.88 CDKN1A CDKN2A PTEN RB1 TP53
27 11.87 CDKN1A PTEN RB1 UBE3A
28 11.8 CDKN1A RB1 TP53
29 11.8 CDKN1A CDKN2B PTEN RB1 TP53
30 11.78 CDKN1A KRT14 KRT5 TP53
31 11.72 CDKN1A CDKN2A TP53
32 11.68 CDKN1A CDKN2A RB1 TP53 UBE3A
33
Show member pathways
11.68 FLG IVL KRT10 KRT13 KRT14 KRT20
34 11.66 FGFR3 PTEN TP53
35 11.58 CDKN1A CDKN2A FGFR3 RB1 TP53
36 11.53 CDKN1A CDKN2A RB1 TP53
37 11.33 CDKN2A CDKN2B TP53
38 11.12 CDKN2A RB1 TP53
39
Show member pathways
11.11 CDKN1A CDKN2A TP53
40 11.02 CDKN1A CDKN2B PTEN RB1 TP53
41 10.76 CDKN1A TP53

GO Terms for Papilloma

Cellular components related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.86 AMOT CDKN1A CDKN2A CDKN2B FLG IVL
2 PML body GO:0016605 9.58 PTEN RB1 TP53
3 keratin filament GO:0045095 9.56 KRT13 KRT14 KRT5 KRT8
4 cornified envelope GO:0001533 9.5 FLG IVL KRT10
5 intermediate filament GO:0005882 9.17 FLG KRT10 KRT13 KRT14 KRT20 KRT5
6 cytoplasm GO:0005737 10.21 CDKN1A CDKN2A CDKN2B FGFR3 IVL KRT10
7 nucleus GO:0005634 10.09 AMOT CDKN1A CDKN2A CDKN2B FGFR3 FLG

Biological processes related to Papilloma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.99 CDKN2A FGFR3 KRT20 PTEN RB1 TP53
2 negative regulation of cell proliferation GO:0008285 9.91 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
3 negative regulation of apoptotic process GO:0043066 9.89 CDKN1A PTEN TGFA TP53
4 G1/S transition of mitotic cell cycle GO:0000082 9.76 CDKN1A CDKN2A RB1
5 keratinocyte differentiation GO:0030216 9.72 FLG IVL KRT10
6 negative regulation of epithelial cell proliferation GO:0050680 9.71 CDKN2B PTEN RB1
7 peptide cross-linking GO:0018149 9.67 FLG IVL KRT10
8 Ras protein signal transduction GO:0007265 9.67 CDKN1A CDKN2A RB1 TP53
9 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.65 CDKN1A CDKN2B PTEN
10 hemidesmosome assembly GO:0031581 9.58 KRT14 KRT5
11 negative regulation of phosphorylation GO:0042326 9.58 CDKN1A CDKN2A CDKN2B
12 response to arsenic-containing substance GO:0046685 9.57 CDKN1A PTEN
13 hepatocyte apoptotic process GO:0097284 9.56 KRT8 RB1
14 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.56 CDKN1A CDKN2B PTEN RB1
15 cell cycle arrest GO:0007050 9.55 CDKN1A CDKN2A CDKN2B RB1 TP53
16 prostate gland growth GO:0060736 9.52 PTEN UBE3A
17 replicative senescence GO:0090399 9.5 CDKN1A CDKN2A TP53
18 keratinization GO:0031424 9.5 IVL KRT10 KRT13 KRT14 KRT20 KRT5
19 signal transduction by p53 class mediator GO:0072331 9.46 CDKN1A TP53
20 cornification GO:0070268 9.23 FLG IVL KRT10 KRT13 KRT14 KRT20

Molecular functions related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 CDKN1A CDKN2A CDKN2B PTEN TP53
2 ubiquitin protein ligase binding GO:0031625 9.67 CDKN1A RB1 TP53 UBE2L3
3 disordered domain specific binding GO:0097718 9.43 CDKN2A RB1 TP53
4 structural molecule activity GO:0005198 9.35 FLG IVL KRT10 KRT13 KRT8
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CDKN1A CDKN2A CDKN2B
6 protein binding GO:0005515 10.11 AMOT CDKN1A CDKN2A CDKN2B FGFR3 FLG

Sources for Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....